Silk Road Medical, Inc (SILK)
Silk Road Medical, Inc operates in the Medical - Devices industry of the Healthcare sector, headquartered in Sunnyvale, CA, US. The stock last traded at $27.49, down 0.04% on the session, giving a market capitalisation of $1.12B. On trailing twelve-month figures it carries a trailing P/E of -19.09, a net margin of -31.5%. Its beta of 1.54 implies it has historically moved more than the broad market.
Silk Road Medical, Inc. operates as an American medical device company, focusing on innovative solutions for carotid artery disease. The firm's product portfolio is specifically engineered to support transcarotid artery revascularization (TCAR) procedures. Among its key offerings is the ENROUTE Transcarotid Neuroprotection System, designed to directly access the common carotid artery and initiate a temporary reversal of blood flow. The company also provides the ENROUTE Transcarotid Stent System, a distinctive stent characterized by its self-expanding and self-tapering capabilities. For streamlined initial entry to the common carotid artery, Silk Road Medical offers the ENHANCE Transcarotid Peripheral Access Kit. Additionally, the ENROUTE 0.014 Guidewire plays a crucial role in navigating and crossing target lesions, enabling the precise delivery of other interventional devices. Founded in 2007, Silk Road Medical, Inc. maintains its primary corporate offices in Sunnyvale, California.
Silk Road Medical, Inc is most often compared with the following Healthcare names: